UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 164

Sortiert nach

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]

PloS one, 2022-06, Vol.17 (6), p.e0258614-e0258614

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Journal of the neurological sciences, 2023-12, Vol.455, p.121718, Article 121718

2023

Link zum Volltext

Verfügbarkeit prüfen

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis

Muscle & nerve, 2023-10, Vol.68 (4), p.397-403

2023

Link zum Volltext

Verfügbarkeit prüfen

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)

Muscle & nerve, 2020-02, Vol.61 (2), p.218-221

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 3B study evaluating superiority of daily dosing vs approved on/off oral edaravone dosing over 48 weeks in patients with amyotrophic lateral sclerosis (MT-1186-A02)

Journal of the neurological sciences, 2023-12, Vol.455, p.121719, Article 121719

2023

Link zum Volltext

Verfügbarkeit prüfen

Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19

Muscle & nerve, 2022-02, Vol.65 (2), p.180-186

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 3B extension study evaluating superiority of daily vs approved on/off oral edaravone dosing in patients with amyotrophic lateral sclerosis

Journal of the neurological sciences, 2023-12, Vol.455, p.121720, Article 121720

2023

Link zum Volltext

Verfügbarkeit prüfen

Design and Performance Characterization of a New Lisa-Like Gravitational Reference Sensor Test-Bed Using the Uf Torsion Pendulum

Apple, Stephen

2020

Link zum Volltext
ProQuest

Current and Future Projections of Amyotrophic Lateral Sclerosis in the United States Using Administrative Claims Data

Neuroepidemiology, 2021-07, Vol.55 (4), p.275-285

2021

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch

Drugs in R&D, 2022-09, Vol.22 (3), p.205-211

2022

Link zum Volltext

Verfügbarkeit prüfen

Characterisation of Au surface properties relevant for UV photoemission-based charge control for space inertial sensors

Classical and quantum gravity, 2020-10, Vol.37 (19), p.195009

2020

Link zum Volltext

Verfügbarkeit prüfen

Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2021-02, Vol.22 (1-2), p.147-150

2021

Link zum Volltext

Verfügbarkeit prüfen

Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2019-07, Vol.20 (5-6), p.421-431

2019

Link zum Volltext

Verfügbarkeit prüfen

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment

Muscle & nerve, 2023-02, Vol.67 (2), p.124-129

2023

Link zum Volltext

Verfügbarkeit prüfen

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48weeks of treatment

Muscle & nerve, 2023-02, Vol.67 (2), p.124-129

2023

Link zum Volltext

Verfügbarkeit prüfen

Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2022-01, Vol.23 (1-2), p.49-57

2022

Link zum Volltext

Verfügbarkeit prüfen

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]

PloS one, 2022-01, Vol.17 (6)

2022

Link zum Volltext

Verfügbarkeit prüfen

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design

Neurology. Clinical practice, 2021-08, Vol.11 (4), p.e472-e479

2021

Link zum Volltext

Verfügbarkeit prüfen

The Routledge International Handbook of the Sociology of Education

Routledge, Taylor & Francis Group, 2009

2009

Link zum Volltext

Verfügbarkeit prüfen

Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, Vol.22 (1-2), p.147-150

2021

Link zum Volltext

Verfügbarkeit prüfen

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

Liver cancer (Basel ), 2020-06, Vol.9 (3), p.245-260

2020

Link zum Volltext

Verfügbarkeit prüfen

High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study

The Lancet (British edition), 2015-12, Vol.386 (10012), p.2481-2488

2015

Link zum Volltext

Verfügbarkeit prüfen

Present and Future of Cardiac Troponin in Clinical Practice: A Paradigm Shift to High-sensitivity Assays

The American journal of medicine, 2016-04, Vol.129 (4), p.354-365

2016

Link zum Volltext

Verfügbarkeit prüfen

Renal Dysfunction Influences the Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin I

Journal of the American Society of Nephrology, 2018-02, Vol.29 (2), p.636-643

2018

Link zum Volltext

Verfügbarkeit prüfen

Supply/Demand Type 2 Myocardial Infarction: Should We Be Paying More Attention?

Journal of the American College of Cardiology, 2014-05, Vol.63 (20), p.2079-2087

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(139)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(164)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)

Phase 3B study evaluating superiority of daily dosing vs approved on/off oral edaravone dosing over 48 weeks in patients with amyotrophic lateral sclerosis (MT-1186-A02)

Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19

Phase 3B extension study evaluating superiority of daily vs approved on/off oral edaravone dosing in patients with amyotrophic lateral sclerosis

Design and Performance Characterization of a New Lisa-Like Gravitational Reference Sensor Test-Bed Using the Uf Torsion Pendulum

Current and Future Projections of Amyotrophic Lateral Sclerosis in the United States Using Administrative Claims Data

Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch

Characterisation of Au surface properties relevant for UV photoemission-based charge control for space inertial sensors

Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study

Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48weeks of treatment

Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design

The Routledge International Handbook of the Sociology of Education

Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study

Present and Future of Cardiac Troponin in Clinical Practice: A Paradigm Shift to High-sensitivity Assays

Renal Dysfunction Influences the Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin I

Supply/Demand Type 2 Myocardial Infarction: Should We Be Paying More Attention?

Suchergebnisse filtern